Suven Life Sciences announced the grant of one (1) product patent from Canada (2907620) corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and this Patent is valid through 2033.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
